Literature DB >> 23723452

High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.

Stella T Chou1, Tannoa Jackson, Sunitha Vege, Kim Smith-Whitley, David F Friedman, Connie M Westhoff.   

Abstract

Red blood cell (RBC) transfusion is a key treatment of patients with sickle cell disease (SCD) but remains complicated by RBC immunization. In the present study, we evaluated the effects of antigen matching for Rh D, C, and E, and K and transfusion from African American donors in 182 patients with SCD. Overall, 71 (58%) chronic and 9 (15%) episodically transfused patients were alloimmunized. Fifty-five (45%) chronic and 7 (12%) episodically transfused patients were Rh immunized. Of 146 antibodies identified, 91 were unexplained Rh antibodies, one-third of which were associated with laboratory evidence of delayed transfusion reactions. Fifty-six antibodies occurred in patients whose RBCs were phenotypically positive for the corresponding Rh antigen and 35 in patients whose RBCs lacked the antigen and were transfused with Rh-matched RBCs. High-resolution RH genotyping revealed variant alleles in 87% of individuals. These data describe the prevalence of Rh alloimmunization in patients with SCD transfused with phenotypic Rh-matched African American RBCs. Our results suggest that altered RH alleles in both the patients and in the donors contributed to Rh alloimmunization in this study. Whether RH genotyping of patients and minority donors will reduce Rh alloimmunization in SCD needs to be examined.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23723452     DOI: 10.1182/blood-2013-03-490623

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  129 in total

1.  Immune Regulation of sickle Cell Alloimmunization.

Authors:  Karina Yazdanbakhsh; Beth H Shaz; Christopher D Hillyer
Journal:  ISBT Sci Ser       Date:  2016-11-15

2.  TIGIT-positive circulating follicular helper T cells and sickle cell alloimmunization.

Authors:  France Pirenne
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 3.  Transfusion-related red blood cell alloantibodies: induction and consequences.

Authors:  Christopher A Tormey; Jeanne E Hendrickson
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

4.  Rh alloimmunization in chronically transfused patients with thalassemia receiving RhD, C, E, and K matched transfusions.

Authors:  Sarah J Waldis; Stacey Uter; Donna Kavitsky; Cynthia Flickinger; Sunitha Vege; David F Friedman; Connie M Westhoff; Stella T Chou
Journal:  Blood Adv       Date:  2021-02-09

5.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-10

6.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2016-10

Review 7.  Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Authors:  Lise J Estcourt; Patricia M Fortin; Sally Hopewell; Marialena Trivella; Carolyn Doree; Miguel R Abboud
Journal:  Cochrane Database Syst Rev       Date:  2017-05-13

Review 8.  How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.

Authors:  France Pirenne; Karina Yazdanbakhsh
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

Review 9.  Transfusion Support of Minority Patients: Extended Antigen Donor Typing and Recruitment of Minority Blood Donors.

Authors:  Jenna Khan; Meghan Delaney
Journal:  Transfus Med Hemother       Date:  2018-07-19       Impact factor: 3.747

Review 10.  Genotyping in Sickle Cell Disease Patients: The French Strategy.

Authors:  Aline Floch; Christophe Tournamille; Btissam Chami; France Pirenne
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.